Maxpro Capital Acquisition (JMAC) Competitors $6.83 +0.56 (+8.93%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock JMAC vs. AMRN, ENGN, GLUE, FHTX, SCPH, CAPR, MNPR, ALEC, MREO, and ANNXShould you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Amarin (AMRN), enGene (ENGN), Monte Rosa Therapeutics (GLUE), Foghorn Therapeutics (FHTX), scPharmaceuticals (SCPH), Capricor Therapeutics (CAPR), Monopar Therapeutics (MNPR), Alector (ALEC), Mereo BioPharma Group (MREO), and Annexon (ANNX). These companies are all part of the "pharmaceutical products" industry. Maxpro Capital Acquisition vs. Its Competitors Amarin enGene Monte Rosa Therapeutics Foghorn Therapeutics scPharmaceuticals Capricor Therapeutics Monopar Therapeutics Alector Mereo BioPharma Group Annexon Amarin (NASDAQ:AMRN) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Do analysts rate AMRN or JMAC? Amarin currently has a consensus price target of $12.00, suggesting a potential downside of 19.62%. Given Amarin's stronger consensus rating and higher possible upside, analysts clearly believe Amarin is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is AMRN or JMAC more profitable? Maxpro Capital Acquisition has a net margin of 0.00% compared to Amarin's net margin of -47.22%. Maxpro Capital Acquisition's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-47.22% -21.18% -15.00% Maxpro Capital Acquisition N/A N/A N/A Does the media prefer AMRN or JMAC? In the previous week, Amarin had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for Amarin and 0 mentions for Maxpro Capital Acquisition. Amarin's average media sentiment score of 0.95 beat Maxpro Capital Acquisition's score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Overall Sentiment Amarin Positive Maxpro Capital Acquisition Neutral Which has stronger earnings and valuation, AMRN or JMAC? Maxpro Capital Acquisition has lower revenue, but higher earnings than Amarin. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.35-$82.18M-$3.67-4.07Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Do institutionals and insiders have more ownership in AMRN or JMAC? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 2.0% of Amarin shares are owned by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, AMRN or JMAC? Amarin has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. SummaryAmarin beats Maxpro Capital Acquisition on 6 of the 11 factors compared between the two stocks. Get Maxpro Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JMAC vs. The Competition Export to ExcelMetricMaxpro Capital AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$91.71M$215.98M$2.56B$10.19BDividend YieldN/A3.12%2.52%4.61%P/E RatioN/A0.1726.3526.40Price / SalesN/A443.70116.01125.99Price / CashN/A123.7050.2629.91Price / BookN/A7.1533.486.28Net IncomeN/A-$11.59M$15.01M$270.38M7 Day Performance32.36%2.72%1.53%2.70%1 Month Performance17.76%-1.73%4.16%5.99%1 Year Performance4,922.06%183.26%35.67%25.94% Maxpro Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JMACMaxpro Capital AcquisitionN/A$6.83+8.9%N/A+4,922.1%$91.71MN/A0.002,021AMRNAmarin0.5439 of 5 stars$14.88-0.8%$12.00-19.4%+25.1%$307.00M$228.61M-4.04360ENGNenGene2.8393 of 5 stars$5.96-5.3%$23.29+291.0%-14.6%$304.30MN/A-3.6131Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionHigh Trading VolumeGLUEMonte Rosa Therapeutics2.8706 of 5 stars$4.91+2.3%$15.33+212.3%-20.9%$303.24M$75.62M13.6490Trending NewsGap UpFHTXFoghorn Therapeutics2.7593 of 5 stars$5.36+4.0%$10.67+99.2%-46.6%$302.72M$22.60M-4.50120Positive NewsSCPHscPharmaceuticals4.5032 of 5 stars$5.63+0.3%$7.78+38.4%+2.6%$299.81M$36.33M-3.1130Short Interest ↓CAPRCapricor Therapeutics2.3562 of 5 stars$6.47+2.1%$22.56+248.9%+38.6%$296.95M$22.27M-3.96101Trending NewsMNPRMonopar Therapeutics3.2921 of 5 stars$46.31+7.9%$71.75+55.0%+1,175.1%$285.70MN/A-13.9110News CoverageAnalyst ForecastGap UpALECAlector3.9105 of 5 stars$2.83-0.5%$4.17+47.5%-54.4%$285.41M$100.56M-2.43270Positive NewsAnalyst UpgradeMREOMereo BioPharma Group2.3332 of 5 stars$1.80+0.8%$7.40+312.3%-56.8%$285.41M$10M-25.6440ANNXAnnexon2.6158 of 5 stars$2.59+12.9%$12.50+383.6%-66.4%$285.17MN/A-2.0160Positive News Related Companies and Tools Related Companies AMRN Competitors ENGN Competitors GLUE Competitors FHTX Competitors SCPH Competitors CAPR Competitors MNPR Competitors ALEC Competitors MREO Competitors ANNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JMAC) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maxpro Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maxpro Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
